Welcome to the e-CCO Library!

P632: Allogenic hPDMSCs gelatum in the treatment of perianal fistulas in patients with Crohn’s disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

J. Tang*1, X. Wu1, X. Cao2, X. Gao1, P. Lan1

Created: Friday, 22 February 2019, 9:41 AM
P632: Comparative analysis of the pharmacokinetics of Inflectra® biosimilar with Remicade® in the induction phase of remission in patients with Crohn's disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Juan G.*1, Mora M.2, Alvariño A.3, Maroto N.2, Ferrer I.2, Hinojosa E.2, Hinojosa M.D.2, Ferrandis P.1, Hinojosa J.2

Created: Wednesday, 20 February 2019, 10:36 AM
P632: Estimating indirect and out-of-pocket disease-associated costs in paediatric Inflammatory Bowel Disease: a nation-wide cross-sectional analysis
Year: 2022
Source: ECCO'22
Authors: El-Matary, W.(1);Witt, J.(2);Bersnstein, C.(3);Jacobson, K.(4);Mack, D.(5);Otley, A.(6);Walters, T.(7);Huynh, H.(8);deBruyn, J.(9);Griffiths, A.(10);Benchimol, E.(10);
Created: Friday, 11 February 2022, 3:56 PM
P632: Etrasimod induction therapy in moderately to severely active Crohn's disease: results from a phase 2, randomised, double-blind substudy
Year: 2023
Source: ECCO’23 Copenhagen
Authors: D'Haens, G.(1)*;Dubinsky, M.C.(2);Peyrin-Biroulet, L.(3,4);Danese, S.(5);Sands, B.E.(6);Wolf, D.C.(7);Yarur, A.(8);Chiorean, M.(9);Dray, D.(10);Modesto, I.(11);Tan, H.(12);Gu, G.(13);Lopez, C.(14);Su, C.(15);Zhang, J.(16);McDonnell, A.(17);Schreiber, S.(18);Feagan, B.G.(19);Vermeire, S.(20);
Created: Friday, 14 July 2023, 11:12 AM
P632: Is the gender or age of the physician key to a good physician-patient with Inflammatory Bowel Disease relationship?
Year: 2021
Source: ECCO'21 Virtual
Authors: García Mateo, S.(1,2);Martínez-Domínguez, S.J.(1,2);Gargallo-Puyuelo, C.J.(1,2,3);Gomollón García, F.(1,2,3,4);
Created: Wednesday, 2 June 2021, 4:12 PM
P632: Trough levels of golimumab at Week 6 predict drug retention rate in ulcerative colitis
Year: 2018
Source: ECCO '18 Vienna
Authors:

S. Stefanovic1*, I. Detrez2, G. Compernolle2, E. Brouwers2, N. Sever1, B. Stabuc1, I. Ferkolj1, N. Smrekar1, G. Novak1, M. Kozelj1, M. Ferrante3, A. Gils2, D. Drobne1

Created: Thursday, 21 February 2019, 9:14 AM
P633 Sustained reduction of IL-23-related cytokines IL-17A and IL-22 in a phase 2 study of mirikizumab in the treatment of patients with moderately-to-severely active ulcerative colitis through week 52
Year: 2020
Source:

ECCO'20 Vienna

Authors:

G.R. D’Haens1, B.E. Sands2, T. Kobayashi3, J.L. Tuttle4, J. Schmitz5, R. Higgs5, S. Ho5, S.E. Sissons5, W.J. Sandborn6

Created: Thursday, 30 January 2020, 10:12 AM
P633: Abstract has been withdrawn.
Year: 2022
Source: ECCO'22
Created: Friday, 11 February 2022, 3:56 PM
P633: Antibodies to infliximab in patients treated with either the reference biologic or the biosimilar CT-P13 show identical reactivity towards biosimilars CT-P13 and SB2 in inflammatory bowel disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Fiorino G.*1, Ruiz-Agüello M.B.2, Maguregui A.2, Nagore D.2, Radice S.1, Gilardi D.1, Correale C.1, Allocca M.1, Furfaro F.1, Alfieri M.1, Martínez A.2, Danese S.1,3

Created: Wednesday, 20 February 2019, 10:36 AM
P633: Choice of first biologic in moderate to severe ulcerative colitis – a decision analysis using time-on-treatment and UK costs
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Dhar, A.(1)*;Wilson, A.(2);Reid, V.(3);Clark, T.(4);Tibbatts, C.(5);Dallongeville, A.(6);Robertson, J.(7);Eaton, J.(8);Cranmer, H.(9);Owen, G.(8);
Created: Friday, 14 July 2023, 11:12 AM
P633: Clinical epidemiology of Inflammatory Bowel Disease in Lbanon
Year: 2021
Source: ECCO'21 Virtual
Authors: Abou Rached, A.(1);Saba, J.(1);Yared, F.(1);saniour, J.(1);Abou Khalil, M.(1);Al Bacha, R.(1);Khalil, P.(1);Bou Jaoude, J.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P633: Concordance between endoscopy and histology scores at baseline and following induction therapy with the JAK1 inhibitor filgotinib in active Crohn’s disease: Results from FITZROY study
Year: 2018
Source: ECCO '18 Vienna
Authors:

W. Reinisch1*, G. De Hertogh2, G. D'Haens3, W. Li4, A. Serone4, C. Tasset5, A. Van der Aa5, S. Vermeire6

Created: Thursday, 21 February 2019, 9:14 AM
P633: Harmonisation of quality of care in an IBD centre impacts disease outcomes: importance of structure and process indicators
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

J. Reinglas*1, S. Restellini2, L. Gonczi3, Z. Kurti3, S. Nene1, R. Kohen1, W. Afif1, T. Bessissow1, G. Wild1, E. Seidman1, A. Bitton1, P. Lakatos1

Created: Friday, 22 February 2019, 9:41 AM
P634 Predictors of response and course in patients with inflammatory bowel disease treated with biological therapy: The Danish IBD-Biobank project
Year: 2020
Source:

ECCO'20 Vienna

Authors:

M. Zhao1, F. Bendtsen1, A.M. Petersen1,2, L. Larsen3, T. Jess3,4, A. Dige5, C. Hvas5, J. Seidelin6, J. Burisch1

Created: Thursday, 30 January 2020, 10:12 AM
P634: Abstract has been withdrawn.
Year: 2022
Source: ECCO'22
Created: Friday, 11 February 2022, 3:56 PM
P634: Clinical and endoscopic remission with vedolizumab treatment in ulcerative colitis
Year: 2018
Source: ECCO '18 Vienna
Authors:

A. Almutairdi, C. Ma*, P.G. Kotze, A. Al-Damarki, S. Devlin, G. Kaplan, C. Seow, K. Novak, C. Lu, J. Ferraz, M. Stewart, M. Buresi, M. Mathivanan, H. Jijon, J. Heatherington, M.-L. Martin, R. Panaccione

Created: Thursday, 21 February 2019, 9:14 AM
P634: Long term risk of relapse after anti-TNF discontinuation based on mucosal healing in inflammatory bowel disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

García Ortíz J.M., Sáenz Gallo M., Trigo Salado C., De La Cruz Ramirez M.D., Marquez Galan J.L., Herrera Justiniano J.M., Bozada García J.M., Leo Carnerero E.

Created: Wednesday, 20 February 2019, 10:36 AM
P634: Real-world data on the efficacy and safety of vedolizumab therapy in patients with inflammatory bowel disease: a retrospective nation-wide cohort study in Singapore
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

A. T-M. Gan*1, W. P-W. Chan1, K. L. Ling1,2, L. J. Hartono3, D. E. Ong3, M. Gowans3, H. Lin4, W. C. Lim4, M. T-K. Tan5, J. P-L. Ong5, B. J. Schwender1, S. C. Kong1, W. C. Ong1, T. G. Lim1, S. W. Chuah6, C. J. Ooi6, H. H. Shim1

Created: Friday, 22 February 2019, 9:41 AM
P634: Trajectories of oral budesonide use in Crohn's disease cohort of Tuscan patients
Year: 2021
Source: ECCO'21 Virtual
Authors: Bertani, L.(1);Ferraro, S.(2);Bartolini, C.(3);Convertino, I.(2);Giometto, S.(2);Cappello, E.(2);Valdiserra, G.(2);Tillati, S.(2);Blandizzi, C.(2);Lucenteforte, E.(2);Gini, R.(3);Tuccori, M.(2,4);Costa, F.(5);
Created: Wednesday, 2 June 2021, 4:12 PM
P634: Ustekinumab and vedolizumab as first-line biological therapy for inflammatory bowel disease. A multicenter study based on the ENEIDA registry.
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Calafat Sard, M.(1,2)*;Pascual, I.(3);Nos, P.(2,4); Barrio, J.(5); Gutiérrez, A.(2,6);Martín-Arranz, M.D.(7);Ricart, E.(2,8);Gomollón, F.(2,9);Sierra Ausín, M.(10); Huguet, J.M.(11);Guardiola, J.(12);Vera, I.(13);Varela, P.(14);Iglesias, E.(15);Garcia-Planella, E.(16);de Castro , L.(17);García Sepulcre , M.F.(18); Sicilia, B.(19);Fernández-Salazar, L.(20); Calvet, X.(2,21);Muñoz, F.(22); García-López, S.(23);Bermejo, F.(24);Ramos, L.(25);Martínez Montiel, P.(26);Lorente, R.(27);Cabriada, J.L.(28);Piqueras, M.(29);Marín-Jiménez, I.(30);Esteve, M.(2,31);Mesonero, F.(32); Sesé, E.(33);P. Gisbert, J.(2,34);Márquez, L.(35);Busquets, D.(36);Pajares, R.(37);Cañete, F.(2,38);Mañosa, M.(2,38);Domènech, E.(2,38);
Created: Friday, 14 July 2023, 11:12 AM